Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial

BACKGROUND: Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PP...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulluck, Heerajnarain, Fröhlich, Georg M, Nicholas, Jennifer M, Mohdnazri, Shah, Gamma, Reto, Davies, John, Sirker, Alex, Mathur, Anthony, Blackman, Daniel, Garg, Pankaj, Moon, James C, Greenwood, John P, Hausenloy, Derek J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mosby 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483973/
https://www.ncbi.nlm.nih.gov/pubmed/30893577
http://dx.doi.org/10.1016/j.ahj.2019.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483973/
https://www.ncbi.nlm.nih.gov/pubmed/30893577
http://dx.doi.org/10.1016/j.ahj.2019.02.005

Ejemplares similares